登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《BioWorld，7月9日，Hong Kong’s med-tech sector looks to leverage technology, funding to expand》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-07-15

  • HONG KONG – Hong Kong’s emerging med-tech sector is getting a boost from a government-funded program aimed at sharing technology with other jurisdictions, a program driven in part by the need to contain the COVID-19 pandemic and continue opening regional economies.

    Hong Kong has a population of about 7.5 million, but with eight publicly funded universities and almost 20 degree-granting institutions as well as an increasingly active startup environment, it is emerging as a medical technology hub.

    The program was jointly launched by the Hong Kong Trade Development Council (HKTDC), the Commerce and Economic Development Bureau (CEDB) and the Innovation and Technology Bureau (ITB). The effort to share technology started in June with Thailand and the plan is to expand it to Indonesia and Malaysia and other countries in the future.

  • 原文来源：https://www.bioworld.com/articles/436348-hong-kongs-med-tech-sector-looks-to-leverage-technology-funding-to-expand
102浏览量
原文链接
相关报告

  • 《Bioworld，2月7日，Hong Kong researchers create fastest coronavirus diagnostic test to date》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-09
    • HONG KONG – A team of researchers at Hong Kong University of Science and Technology (HKUST) claim to have invented the world’s fastest portable 2019-nCoV diagnostic device. From sampling to testing, the device is apparently able to detect the novel coronavirus in just 40 minutes. In comparison, the polymerase chain reaction (PCR) technology that is currently in use can take between 1.5 to 3 hours.
    53浏览量
    原文链接

  • 《BioWorld，7月9日，Mylan gets remdesivir approval for COVID-19 in India》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-07-15
    • Mylan gets remdesivir approval for COVID-19 in India July 9, 2020 By David Ho HONG KONG – The Drug Controller General of India (DCGI) has approved Mylan NV’s remdesivir 100-mg vial for restricted emergency use in COVID-19 cases. The drug received an accelerated approval for the treatment of COVID-19 in adults and children hospitalized with severe presentations of the disease. It will be released in India under the brand name Desrem, and be available to patients at a price of INR4,800 (US$64.34) this month. Mylan claims its price for the India market is more than 80% less than the price at which the branded version of remdesivir will be available to governments in the developed world. Its remdesivir will be manufactured in India at its injectables facilities there. Mylan is one of the six Indian pharma companies that have received nonexclusive licenses from Gilead Sciences Inc. to manufacture and distribute generic remdesivir in 127 low- and middle-income countries. The approval from the DCGI in India represents the first for Mylan in those 127 markets.
    73浏览量
    原文链接